Nodamura Virus B2 Protein-Based Broad Spectrum Antiviral

Description:

Expression of the Nodamura virus B2 protein in human and mouse cell lines suppresses the accumulation of a unique class of non-coding small RNAs derived from the chikungunya virus genome. Significant decreases in virus replication correlates well with B2-mediated suppression of these non-coding RNAs.

We suspect that the non-coding RNAs identified by our studies are similar to short viral leader RNAs (leRNAs) previously identified only in the genomes of negative-strand viruses. leRNAs are believed to be essential to the replication of the negative-strand viruses from which they have been identified. Our discovery of leRNAs derived from chikungunya virus, which is a positive-strand virus, suggests these non-coding RNAs may be present in a broad spectrum or even all RNA viruses.

The Nodamura virus B2 protein has tremendous potential for development as a broad spectrum antiviral.

Patent Information:
Category(s):
Biotechnology
Biomedical
For Information, Contact:
Mike Miller
Senior Licensing Manager
Virginia Tech Intellectual Properties, Inc.
(540) 443-9228
mmiller@vtip.org
Inventors:
Kevin Myles
Zach Adelman
Keywords:
© 2017. All Rights Reserved. Powered by Inteum